Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month open-label safety study of pregabalin adjunctive therapy in pediatric partial seizures and pediatric/adult primary generalized tonic-clonic seizures
MOH_2017-08-24_000761Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pregabalin in epilepsy, Focal onset seizure and primary generalized tonic-clonic seizure (PGTCS), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability of pregabalin. Started Oct 2014; status: recruiting.
02
Drugs
pregabalin
03
Conditions
epilepsyFocal onset seizureprimary generalized tonic-clonic seizure (PGTCS)
Beyond the preview
Go deeper on MOH_2017-08-24_000761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-24_000761.